2023 No. 1

2023 No.1

Theme Issue: Expanding Antiviral Treatment of Chronic Hepatitis B

Executive Chief Editor: ZHUANG Hui

School of Basic Medical Sciences, Peking University

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

Expanding the treatment of chronic hepatitis B

Hui ZHUANG

2023, 39(1): 10-13. DOI: 10.3969/j.issn.1001-5256.2023.01.001

Abstract(2805)

HTML (1690)

PDF (3154KB)(479)

Abstract:

Among chronic hepatitis B patients eligible for treatment, only 5% have received antiviral therapy worldwide. The strictness of treatment criteria in current guidelines is one of the contributing factors for the low treatment rate of patients with chronic hepatitis B, and expanding the treatment cri...

Discussions by Experts

Thoughts on expert opinion on expanding antiviral therapy for chronic hepatitis B

Zhihong LIU, Xieer LIANG, Jinlin HOU

2023, 39(1): 14-21. DOI: 10.3969/j.issn.1001-5256.2023.01.002

Abstract(2311)

HTML (1446)

PDF (1852KB)(298)

Abstract:
Expanding antiviral therapy is currently the new trend for the diagnosis and treatment of chronic hepatitis B, and related research evidence should be studied and discussed. Reducing the threshold of alanine aminotransferase (ALT) for initiating antiviral therapy is one of the most important changes...

Expanding the indications for antiviral therapy for chronic hepatitis B: Advantages and disadvantages

Chao HAN, Xiaoguang DOU

2023, 39(1): 22-26. DOI: 10.3969/j.issn.1001-5256.2023.01.003

Abstract(2364)

HTML (1418)

PDF (1731KB)(231)

Abstract:
Chronic hepatitis B (CHB) is a chronic progressive disease caused by hepatitis B virus (HBV), and without timely and effective antiviral therapy, it will eventually develop into liver cirrhosis, liver failure or hepatocellular carcinoma (HCC). Early initiation of antiviral therapy can prevent or del...

Expanding initial anti-HBV therapy for chronic hepatitis B: Reducing the treatment threshold of alanine aminotransferase

Jiayi ZHANG, Shuyan CHEN, Hong YOU

2023, 39(1): 27-30. DOI: 10.3969/j.issn.1001-5256.2023.01.004

Abstract(2176)

HTML (1378)

PDF (1717KB)(223)

Abstract:
In order to achieve the global goal of eliminating viral hepatitis as a public health threat by 2030 proposed by the World Health Organization, it is of great importance to expand the treatment of chronic hepatitis B patients. Recent studies have shown that alanine aminotransferase (ALT) is associat...

Early initiation of antiviral therapy reduces the risk of hepatocellular carcinoma in individuals with chronic hepatitis B virus infection

Zhao ZHOU, Abulaiti ABUDUREXITI, Zhiqiang GU, Jing CHANG, Xin LIU, Fengmin LU

2023, 39(1): 31-36. DOI: 10.3969/j.issn.1001-5256.2023.01.005

Abstract(2617)

HTML (1258)

PDF (2209KB)(280)

Abstract:
Chronic hepatitis B virus (HBV) infection is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). From chronic HBV infection to HCC, most patients go through the stages of chronic hepatitis, liver cirrhosis, and HCC. During this long process, the ongoing integration...

Academic Contention

Do HBV DNA-negative HBsAg-positive patients with compensated hepatitis B cirrhosis need antiviral therapy?

Li SU, Jinghang XU, Yaomin LIU, Guomin ZHANG, Yuting GUO, Guiqiang WANG

2023, 39(1): 37-42. DOI: 10.3969/j.issn.1001-5256.2023.01.006

Abstract(2494)

HTML (1426)

PDF (1750KB)(224)

Abstract:
Hepatitis B virus (HBV) infection is a common cause of liver disease in China, and with the continuous progress in the research on antiviral therapy for chronic hepatitis B, the indications for antiviral therapy are constantly expanding. However, there are still controversies over the indications fo...

Guideline Interpretation

Highlights of the EASL clinical practice guidelines on sclerosing cholangitis versus the latest Chinese guideline

Xin SUN, Tingyu ZHANG, Yuhao YAO, Ziwei GUO, Jiaxin ZHANG, Yongan YE, Xiaoke LI

2023, 39(1): 43-49. DOI: 10.3969/j.issn.1001-5256.2023.01.007

Abstract(2507)

HTML (1283)

PDF (1758KB)(221)

Abstract:
In 2022, the European Association for the Study of the Liver issued Clinical practice guidelines on sclerosing cholangitis. With reference to the 2017 edition of Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for th...

Original Article_Viral Hepatitis

Serum levels of soluble programmed death-1 and soluble programmed death-ligand 1 in chronic hepatitis B patients with clinical cure and their clinical features

Ning TAN, Jianxiang LIU, Qian KANG, Jiali PAN, Yifan HAN, Hongyu CHEN, Xiaoyuan XU

2023, 39(1): 50-55. DOI: 10.3969/j.issn.1001-5256.2023.01.008

Abstract(1964)

HTML (1325)

PDF (1747KB)(124)

Abstract:
Objective To investigate the serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in chronic hepatitis B (CHB) patients with clinical cure, the correlation between programmed death-1 (PD-1) and lymphocytes by flow cytometry, and the recovery of hepatitis ...

Expression levels of HBV pregenomic RNA and hepatitis B core-related antigen in circulating serum and their association with recurrence in chronic hepatitis B patients after withdrawal from nucleos(t)ide analogues

Shiwan ZHANG, Xing CHEN, Jiao LIU, Min ZHAO, Xiaoping MEI

2023, 39(1): 56-62. DOI: 10.3969/j.issn.1001-5256.2023.01.009

Abstract(1887)

HTML (1295)

PDF (2010KB)(116)

Abstract:
Objective To investigate the expression levels of HBV pregenomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in circulating serum of chronic hepatitis B (CHB) patients after withdrawal from nucleos(t)ide analogues (NUC), as well as the correlation of HBV pgRNA and HBcrAg levels in circ...

Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis

Xiaoyan MA, Yun CHEN, Jiacheng LIU, Jie LI, Chao WU

2023, 39(1): 63-69. DOI: 10.3969/j.issn.1001-5256.2023.01.010

Abstract(1857)

HTML (1312)

PDF (2358KB)(155)

Abstract:
Objective To investigate the changes of clinical indices in chronic hepatitis B (CHB) patients with concomitant minimal hepatic steatosis and related factors for minimal hepatic steatosis. Methods A total of 179 CHB patients who underwent liver biopsy in Department of Infectious Diseases, Affiliated...

Clinical characteristics and prognosis of acute on chronic liver failure in patients with recompensatory hepatitis B cirrhosis

Lei LIU, Jing LIANG, Baiguo XU, Fei WANG, Jia LIAN, Yankai YANG

2023, 39(1): 70-76. DOI: 10.3969/j.issn.1001-5256.2023.01.011

Abstract(1968)

HTML (1278)

PDF (2214KB)(119)

Abstract:
Objective To assess the clinical characteristics of acute-on-chronic liver failure in patients with recompensatory hepatitis B cirrhosis. Methods A total of 180 patients with acute-on-chronic liver failure hospitalized in Tianjin Third Central Hospital from September 2013 to September 2021 were retr...

Expression and significance of immune cells in patients with hepatitis B virus-related acute-on-chronic pre-liver failure

Fang WANG, Jianhua LU, Yonggang LIU, Xinyu ZHANG, Huimin YAN

2023, 39(1): 77-82. DOI: 10.3969/j.issn.1001-5256.2023.01.012

Abstract(1961)

HTML (1212)

PDF (1963KB)(94)

Abstract:
Objective To investigate the expression of myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), IL-17-producing CD4⁺ T cells (Th17), and CD8⁺ T cells (Tc17) in hepatitis B virus-related acute-on-chronic pre-liver failure (pre-ACHBLF), and to provide ideas for the early treatment of ac...

Original Article_Fatty Liver Disease

Association between serum alkaline phosphatase and type 2 diabetes mellitus with nonalcoholic fatty liver disease

Fangfang QIAN, Meiqing DAI, Li ZHAO, Xia DENG, Ling YANG, Jue JIA, Jifang WANG, Dong WANG, Guoyue YUAN

2023, 39(1): 83-88. DOI: 10.3969/j.issn.1001-5256.2023.01.013

Abstract(2089)

HTML (1417)

PDF (1751KB)(138)

Abstract:
Objective To investigate the association between serum alkaline phosphatase (ALP) and type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Methods A total of 599 patients with T2DM who were hospitalized in Department of Endocrinology, Affiliated Hospital of Jiangsu Universi...

Role of glutathione transferase in nonalcoholic fatty liver disease: An analysis based on gene expression profile

Tingting SHEN, Gerui ZHU, Fan WANG, Xin SUN, Kai HUANG, Yuan PENG, Yanyan TAO, Chenghai LIU

2023, 39(1): 89-96. DOI: 10.3969/j.issn.1001-5256.2023.01.014

Abstract(2222)

HTML (1296)

PDF (4657KB)(132)

Abstract:
Objective To investigate the role of glutathione transferase in nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet using the RNA-Seq technique in combination with gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of differentially expressed gene...

Original Article_Autoimmune Liver Disease

Diagnostic value of real-time shear wave elastography for liver fibrosis in patients with autoimmune hepatitis

Xuexin WANG, Yingxia LI, Libin JIANG, Mingxia ZHOU, Dapeng WEI, Xiaopeng ZHANG, Hongtao WEN

2023, 39(1): 97-103. DOI: 10.3969/j.issn.1001-5256.2023.01.015

Abstract(2013)

HTML (1361)

PDF (1990KB)(105)

Abstract:
Objective To explore the diagnostic value of Young's modulus obtained by real-time shear wave elastography (SWE) for liver fibrosis in autoimmune hepatitis (AIH) patients. Methods A total of 75 AIH patients in the First Affiliated Hospital of Zhengzhou University from January 2013 to April 2022 were...

Original Article_Liver Fibrosis and Liver Cirrhosis

Hemodynamic characteristics of proper hepatic artery and portal vein in patients after splenectomy and devascularization

Xiaofei ZHAO, Daobing ZENG, Guangming LI, Qingliang GUO, Liang DI, Jing DING

2023, 39(1): 104-109. DOI: 10.3969/j.issn.1001-5256.2023.01.016

Abstract(1951)

HTML (1269)

PDF (1732KB)(91)

Abstract:
Objective To investigate the characteristics of hemodynamics of proper hepatic artery and portal vein after splenectomy and devascularization. Methods The clinical data of 103 patients with portal hypertension who underwent splenectomy and devascularization in the Capital Medical University-Affiliat...

Original Articles_Liver Neoplasm

Establishment and validation of a nomogram risk prediction model for infection complications in patients after hepatectomy for liver cancer

Mingqiang ZHU, Dashuai YANG, Xiangyun XIONG, Junpeng PEI, Yang PENG, Youming DING

2023, 39(1): 110-117. DOI: 10.3969/j.issn.1001-5256.2023.01.017

Abstract(1937)

HTML (1375)

PDF (2267KB)(129)

Abstract:
Objective To investigate the risk factors of infection after hepatectomy for liver cancer, and to establish and validate a risk prediction model. Methods The clinical data of 167 patients with primary liver cancer who underwent hepatectomy in People's Hospital of Wuhan University from January 2020 t...

Predictive value of preoperative alkaline phosphatase to prealbumin ratio in prognosis and postoperative complications in patients with hepatocellular carcinoma after radical tumor resection

Shengdeng CHEN, Zhiqiang MOU, Zhongyao CHEN, Jian WEN, Qiu LI

2023, 39(1): 118-127. DOI: 10.3969/j.issn.1001-5256.2023.01.018

Abstract(1959)

HTML (1513)

PDF (2364KB)(100)

Abstract:
Objective To explore the predictive value of preoperative alkaline phosphatase to prealbumin ratio (APR) in prognosis and postoperative complications for patients with hepatocellular carcinoma (HCC) after radical tumor resection. Methods A total of 217 HCC patients who underwent radical tumor resect...

Expression of peripheral CD100 and its regulation to T lymphocytes function in patients with hepatocellular carcinoma

Huijuan FAN, Chun SONG

2023, 39(1): 128-136. DOI: 10.3969/j.issn.1001-5256.2023.01.019

Abstract(1794)

HTML (1285)

PDF (3538KB)(83)

Abstract:
Objective To investigate the changes of peripheral CD100 in patients with hepatocellular carcinoma (HCC), and to assess the regulatory function of CD100 to T lymphocytes in HCC patients. Methods A prospective study was conducted. Fifty-seven HCC patients and twenty-two controls who were hospitalized...

Original Articles_Other Liver Disease

Association of energy metabolism with serum thyroid hormone levels in patients with liver failure and their impact on prognosis

Xing LIU, Ming KONG, Xin HUA, Yinchuan YANG, Manman XU, Yanzhen BI, Lu LI, Zhongping DUAN, Yu CHEN

2023, 39(1): 137-141. DOI: 10.3969/j.issn.1001-5256.2023.01.020

Abstract(1926)

HTML (1330)

PDF (1774KB)(116)

Abstract:
Objective To explore the predictive value of the model for end-stage liver disease (MELD) score, energy metabolism and serum thyroid hormone levels on the severity and prognosis of patients with liver failure and their correlation. Methods This study collected clinicopathological data from 60 liver ...

Case Report

Focal nodular hyperplasia-like nodules in liver cirrhosis: An imaging analysis of three cases

Zinan LI, Shaoshan TANG, Xingni WU, Xiang LI

2023, 39(1): 142-146. DOI: 10.3969/j.issn.1001-5256.2023.01.021

Abstract(1955)

HTML (1751)

PDF (3394KB)(107)

Abstract:

A case of chronic gelatinous ascites caused by giant intraductal papillary mucinous neoplasm of the bile tract

Congying CHEN, Ruling ZHANG, Liang QIAO, Lungen LU, Hui ZHOU

2023, 39(1): 147-151. DOI: 10.3969/j.issn.1001-5256.2023.01.022

Abstract(1919)

HTML (1258)

PDF (2992KB)(105)

Abstract:

Primary mucoepidermoid carcinoma of the liver: A case report and literature review

Junjie WANG, Cheng CHEN, Yakun WU

2023, 39(1): 152-155. DOI: 10.3969/j.issn.1001-5256.2023.01.023

Abstract(1758)

HTML (1335)

PDF (3007KB)(105)

Abstract:

Review

Research advances in tenofovir alafenamide fumarate in treatment of special chronic hepatitis B

Yuwen SONG, Lili SHA, Lizhen CHEN, Mengkun LI, Yurong WANG, Yongning XIN

2023, 39(1): 156-161. DOI: 10.3969/j.issn.1001-5256.2023.01.024

Abstract(2836)

HTML (1521)

PDF (1746KB)(259)

Abstract:
There are a large number of individuals with HBV infection in China, which seriously endangers public health safety. As a first-line drug used in clinical practice, tenofovir alafenamide fumarate (TAF) has the characteristics of strong efficacy, low drug resistance, and bone and kidney safety. This ...

Role of glucose and lipid metabolism mediated by the bile acid receptor Takeda G protein-coupled receptor 5 in nonalcoholic fatty liver disease

Xiaoxia XUN, Cheng ZHOU, Wenxia ZHAO

2023, 39(1): 162-167. DOI: 10.3969/j.issn.1001-5256.2023.01.025

Abstract(2347)

HTML (1779)

PDF (2460KB)(163)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) has gradually become a prominent cause affecting human liver health, and the development and progression of NAFLD are associated with metabolic dysfunction, with glucose and lipid metabolism disorder as the key link in this process. Takeda G protein-coupled r...

Mechanism of lipid metabolism mediated by hepatokines and adipokines in nonalcoholic fatty liver disease

Chenlu ZHAO, Dongfang SHANG, Cheng ZHOU, Junhao SHI, Wenxia ZHAO

2023, 39(1): 168-174. DOI: 10.3969/j.issn.1001-5256.2023.01.026

Abstract(2117)

HTML (1473)

PDF (2171KB)(140)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) has been renamed as metabolic-associated fatty liver disease, and systemic metabolic dysfunction has become one of the concerns of this disease. NAFLD is a metabolic disease based on dyslipidemia in the liver, which is closely associated with adipose tissue. ...

Role of pyroptosis in nonalcoholic fatty liver disease

Jingya YIN, Bingqing YANG, Yue LI

2023, 39(1): 175-180. DOI: 10.3969/j.issn.1001-5256.2023.01.027

Abstract(2246)

HTML (1574)

PDF (2197KB)(187)

Abstract:
As a novel mode of cell death, pyroptosis plays an important role in nonalcoholic fatty liver disease (NAFLD), and the research on pyroptosis may help to explore new therapeutic targets for NAFLD. This article reviews the advances in pyroptosis from the research background and mechanism of pyroptosi...

Role of organelle interaction in the development and progression of nonalcoholic fatty liver disease

Tianhui LIU

2023, 39(1): 181-187. DOI: 10.3969/j.issn.1001-5256.2023.01.028

Abstract(2050)

HTML (1619)

PDF (2742KB)(121)

Abstract:
In addition to its own specific functions, an organelle can also interact with other organelles to complete important physiological functions. The disorders of organelle interactions are closely associated the development and progression of various diseases. In recent years, the role of organelle in...

Treatment of primary biliary cholangitis by targeting intestinal flora

Minghan MA, Yanqi LIU

2023, 39(1): 188-191. DOI: 10.3969/j.issn.1001-5256.2023.01.029

Abstract(1993)

HTML (1341)

PDF (1734KB)(122)

Abstract:
Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease targeting biliary epithelial cells, and the concept of "treating diseases by intervening with the gut" has become a research hotspot in recent years. In the future, probiotics may be used to improve the abundance and distri...

Research advances in the reversal of liver fibrosis

Manbiao LI, Jinyu LI, Duiping FENG

2023, 39(1): 193-198. DOI: 10.3969/j.issn.1001-5256.2023.01.030

Abstract(2729)

HTML (2025)

PDF (1748KB)(393)

Abstract:
Chronic liver injury caused by any etiology will lead to liver fibrosis, and it was believed in the past that liver fibrosis is a static and irreversible pathophysiological process. In recent years, with the rapid development of molecular biology and the in-depth research on the microscopic aspect o...

Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

Shimei WANG, Liping WU, Ling HU

2023, 39(1): 199-203. DOI: 10.3969/j.issn.1001-5256.2023.01.031

Abstract(1920)

HTML (1293)

PDF (1745KB)(151)

Abstract:
Portal vein thrombosis is one of the common complications of liver cirrhosis, and anticoagulation is currently the main treatment method for this disease. Since low-molecular-weight heparin must be injected and vitamin K antagonists require regular monitoring of international normalized ratio (INR),...

Research advances in systemic inflammatory response of acute decompensated cirrhosis patients

Hui QUAN, Yuyong JIANG, Yixin HOU, Tingting JIANG, Rongbing WANG

2023, 39(1): 205-210. DOI: 10.3969/j.issn.1001-5256.2023.01.032

Abstract(2005)

HTML (1281)

PDF (1745KB)(91)

Abstract:
Acute decompensated cirrhosis is a stage of end-stage liver disease during which patients often experience decompensated complications and rapid progression. Systemic inflammatory response is characterized by excessive secretion of inflammatory factors caused by bacterial infection of local tissue a...

Application and potential value of endogenous lipid mediators in liver failure

Gengjie YAN, Yong LIN, Huiji SU, Hanxiao CHEN, Shaoqun BAN, Ailing WEI, Dewen MAO, Fuli LONG

2023, 39(1): 211-217. DOI: 10.3969/j.issn.1001-5256.2023.01.033

Abstract(1991)

HTML (1208)

PDF (1761KB)(65)

Abstract:
Liver failure is a common end-stage liver disease syndrome in clinical practice characterized by massive necrosis of hepatocytes leading to rapid liver failure, and it is currently believed that excessive inflammation and immune response are the core mechanisms of this disease. Endogenous lipid medi...

Immune escape of hepatic echinococcosis based on the PD-1/PD-L1 signaling pathway

Kangjie YANG, Yongliang LU, Weijian E

2023, 39(1): 218-225. DOI: 10.3969/j.issn.1001-5256.2023.01.034

Abstract(2063)

HTML (1400)

PDF (2422KB)(220)

Abstract:
PD-1 and PD-L1 together constitute the stimulus signaling pathway of adaptive immune response, which has been widely used in the research on the mechanism of tumor immune escape and tumor therapy. At the same time, its signaling pathway has been proved to be closely associated with the immune escape...

Research advances in the impact of phthalates on cholestatic liver disease

Jiayi ZHANG, Jianqing WANG

2023, 39(1): 226-230. DOI: 10.3969/j.issn.1001-5256.2023.01.035

Abstract(1926)

HTML (1237)

PDF (1856KB)(71)

Abstract:
Cholestatic liver disease is a common hepatobiliary disease caused by bile deposition in the liver due to the disorders of bile production, excretion, and metabolism. At present, the pathogenic factors for cholestatic liver disease have not been fully elucidated, but some researchers believe that en...

Research advances in the risk factors for recurrence of common bile duct stone after choledocholithotomy

Jiqiang LI, Guixin ZHANG

2023, 39(1): 231-237. DOI: 10.3969/j.issn.1001-5256.2023.01.036

Abstract(2290)

HTML (1705)

PDF (1753KB)(140)

Abstract:
Cholelithiasis is a common and frequent disease of the digestive system, and its incidence rate tends to increase with the improvement of living standards. Patients suffering from both gallbladder stones and common bile duct stones account for 5%-15%. Choledocholithiasis can cause a series of seriou...

Introduction of High-quality Articles in Foreign Journals

Hepatology International｜Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma

2023, 39(1): 21-21. DOI: 10.3969/j.issn.1001-5256.2023.01.gwjpwzjj1

Abstract(1610)

HTML (1201)

PDF (768KB)(74)

Abstract:

Hepatology International｜Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials

2023, 39(1): 136-136. DOI: 10.3969/j.issn.1001-5256.2023.01.gwjpwzjj2

Abstract(1697)

HTML (1304)

PDF (770KB)(111)